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ABSTRACT	
	
Ribosomes	are	ribonucleoprotein	complexes	present	 in	every	cell	type,	their	main	function	
being	 the	 synthesis	 of	 proteins,	 ribosomal	 proteins	 included.	 Ribosome	 biogenesis	 is	 the	
process	by	which	the	different	elements	forming	the	two	ribosomal	subunits	are	synthesized	
and	assembled.	Since	almost	all	cellular	activities	depend	on	the	protein	synthesis	capacity	of	
the	 cell,	 an	 Impaired	 Ribosome	 Biogenesis	 Checkpoint	 (IRBC)	 has	 evolved	 to	monitor	 the	
proper	execution	of	ribosome	synthesis.	This	checkpoint	allows	the	cell	to	identify	alterations	
during	the	process	of	ribosome	production,	and,	in	case	of	any	impairment,	a	p53-mediated	
response	will	be	activated.	This	p53	upregulation	is	the	result	of	the	activation	of	a	signaling	
cascade	mediated	by	components	of	the	ribosome,	as	we	will	see	along	this	assignment.	
	
The	present	work	aims	 to	overview	the	 factors	 that	 lead	 to	 the	activation	of	 the	 Impaired	
Ribosome	Biogenesis	Checkpoint,	as	well	as	the	main	pathologies	derived	from	its	activation	
or	 suppression	 (ribosomopathies	 and	 cancer),	 and	 to	 study	 the	 impact	 of	 translation	 in	 a	
cancer	setting.	In	this	regard,	two	techniques	used	to	study	the	engagement	in	translation	of	
mRNAs	(polysome	profiling	and	ribosome	profiling)	will	be	 introduced	and	described	along	
this	work.	These	techniques	will	be	accompanied	by	illustrative	examples	that	will	enable	their	
comprehension	 and	 will	 help	 at	 better	 understanding	 the	 role	 of	 ribosome	 biogenesis	 in	
cancer.	
	
RESUM	
	
Els	ribosomes	són	complexes	formats	per	proteïnes	i	àcids	ribonucleics	presents	en	tots	els	
tipus	 de	 cèl·lules,	 i	 la	 seva	 funció	 principal	 és	 la	 síntesi	 de	 proteïnes,	 incloent	 les	 pròpies	
proteïnes	 ribosomals	 que	 els	 formen.	 La	 biogènesi	 ribosomal	 és	 el	 procés	 pel	 qual	 es	
sintetitzen	els	diferents	elements	que	més	tard	conformaran	les	dues	subunitats	ribosomals.	
Donat	que	una	gran	part	de	l’activitat	cel·lular	depèn	de	la	capacitat	de	síntesi	proteica	de	la	
cèl·lula,	aquesta	ha	desenvolupat,	al	 llarg	de	 l’evolució,	un	punt	de	control	anomenat	 IRBC	
(Impaired	Ribosome	Biogenesis	Checkpoint),	que	és	capaç	de	monitoritzar	alteracions	en	el	
procés	de	síntesi	ribosomal	i	d’activar	una	resposta	mediada	per	p53.	Aquesta	resposta	serà	
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el	resultat	de	l’activació	d’una	cascada	de	senyalització	mediada	per	components	del	propi	
ribosoma,	tal	i	com	veurem	al	llarg	d’aquest	treball.	
	
En	la	present	revisió,	s’introduiran	quins	són	els	factors	que	porten	a	activar	el	punt	de	control	
de	la	biogènesi	ribosomal,	així	com	les	principals	patologies	que	es	deriven	d’aquesta	activació	
o	 inactivació	 (ribosomopaties	 i	 càncer),	 i	 també	s’estudiarà	 l’impacte	de	 la	 traducció	en	el	
marc	 del	 càncer.	 A	 més,	 s’introduiran	 dues	 tècniques	 utilitzades	 en	 l’estudi	 del	 grau	 de	
traducció	de	mRNAs	(polysome	profiling	 i	ribosome	profiling),	que	proporcionen	informació	
sobre	el	nivell	de	traducció	dels	mRNA.	Aquestes	dues	tècniques	s’acompanyaran	d’exemples	
il·lustratius	que	facilitaran	la	seva	comprensió	i	que	ens	ajudaran	a	entendre	millor	quin	és	el	
paper	de	la	biogènesi	ribosomal	en	el	càncer.	
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INTEGRATING	EDUCATIONAL	FIELDS	
	
The	 elaboration	 of	 this	 work	 has	 been	 supported	 by	 the	 integration	 of	 three	 different	
disciplines,	in	order	to	rationally	approach	and	interrelate	the	educational	contents	imparted	
over	the	Pharmacy	degree,	to	finally	apply	the	acquired	knowledge	to	develop	a	subject	of	
interest	in	the	pharmaceutical	field.	
	
Biochemistry	and	molecular	biology	 is	 the	main	 field	of	 this	assignment.	 It	has	allowed	to	
describe	the	processes	and	pathways	of	ribosome	biogenesis	and	its	impairment,	as	well	as	
the	methods	used	for	its	study.	This	field	has	also	contributed	to	explaining	and	linking	the	
molecular	 mechanisms	 by	 which	 ribosomopathies	 and	 cancer	 occur	 upon	 ribosome	
biogenesis	impairment.	
	
Physiology	and	physiopathology	provided	the	knowledge	to	recognize	the	distinct	signs	and	
symptoms	of	ribosome	biogenesis	impairment,	as	well	as	understanding	and	identifying	the	
differences	between	two	diseases	underlying	ribosome	biogenesis	impairment.	
	
Cellular	Biology	has	enabled	to	understand	the	physiological	attributes	of	ribosomes	and	the	
metabolic	processes	by	which	ribosome	biogenesis	occurs.	This	discipline	has	also	helped	at	
understanding	 through	 which	 signalling	 pathways	 the	 ribosome	 biogenesis	 impairment	
affects	the	progression	of	cell	cycle.	
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INTRODUCTION	
	
What	are	ribosomes?	
	
Ribosomes	 are	 the	 ribonucleoprotein	 complexes	 responsible	 of	 decoding	 the	 genetic	
information	 into	proteins	and	accountable	 for	 the	production	of	 the	cellular	biomass.	This	
basic	 cellular	 function	 is	 essential	 for	 life[1],	 explaining	 why	 ribosomes	 are	 universally	
distributed	 thorough	 the	 prokaryote	 and	 eukaryote	 kingdoms.	 Indeed,	 they	 belong	 to	 the	
most	ancient	collection	of	cellular	machineries	evolved	in	life.	
	
Both	in	eukaryotes	and	prokaryotes,	ribosomes	are	found	within	the	cytoplasm.	Prokaryotic	
ribosomes	(70S)	are	more	simple	than	eukaryotic	ribosomes	(80S),	containing	fewer	ribosomal	
proteins	and	fewer	rRNAs,	resulting	in	smaller	subunits.	However,	eukaryotic	cells	also	contain	
70S	ribosomes,	which	are	found	inside	mitochondria	and,	in	plantae,	inside	chloroplasts,	as	a	
result	of	the	symbiosis	of	eukaryotic	cells	with	prokaryotic	organisms	several	million	years	ago.	
In	 eukaryotes,	 ribosomes	 can	 also	 be	 found	 attached	 to	 the	 endoplasmic	 reticulum	 (ER),	
translating	 mRNAs	 that	 encode	 for	 proteins	 destined	 to	 a	 number	 of	 different	 cellular	
functions,	 for	 example,	 the	 ones	 that	 will	 transit	 through	 the	 secretory	 pathway[2].	
Importantly,	 a	 single	 mRNA	 molecule	 can	 be	 translated	 by	 many	 ribosomes	 that	
independently	 associate	 and	 decode	 the	 nucleotide	 sequence,	 simultaneously	 generating	
multiple	copies	of	the	same	protein	from	just	one	mRNA	template.	This	structure	is	termed	
polysome	and	is	often	found	associated	with	the	ER	membranes.	
	
As	 stated	before,	 ribosomes	are	 formed	by	about	80	proteins,	 termed	Ribosomal	Proteins	
(RPs),	 which	 in	 turn	 require	 other	 ribosomes	 for	 their	 synthesis.	 The	 amount	 of	 newly	
synthesized	RPs	determines	the	rate	at	which	new	ribosomes	are	formed	and	vice-versa,	the	
number	of	available	ribosomes	affects	the	pool	of	RPs	produced.	This	mutual	influence	leads	
us	to	 look	 in	more	details	the	process	by	which	new	ribosomes	are	formed,	also	known	as	
ribosome	biogenesis.	
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Ribosome	biogenesis	
	
Ribosome	biogenesis	is	a	critical,	greatly	elaborated	and	well-coordinated	cellular	process	in	
the	 life	 cycle	 of	 a	 cell,	 required	 for	 a	 correct	 cellular	 activity	 and	 function.	 It	 starts	 in	 the	
nucleolus,	a	special	compartment	within	the	nucleus[3],	and	requires	four	different	kinds	of	
rRNAs,	 about	 80	RPs	 and	 the	 activity	 of	 three	RNA	polymerases,	 alongside	 a	 considerable	
number	of	accessory	factors	and	small	nucleolar	RNAs	(snoRNAs).	
	
Ribosomal	 Proteins	 (RPs),	 are	 a	 family	 of	 RNA	 binding	 proteins	 and	 constitute	 a	 core	
component	of	the	ribosome,	playing	a	leading	role	in	mRNA	translation.	The	multiple	roles	of	
RPs	 span	 from	 stabilizing	 rRNAs	 and	 promoting	 their	 correct	 folding	 for	 the	 assembly	 of	
ribosomal	subunits,	to	mediating	the	catalytic	activity	required	in	protein	synthesis.	However,	
over	the	last	years,	several	studies	indicate	that	RPs	are	also	able	to	perform	extraribosomal	
functions	beyond	protein	synthesis,	such	as	DNA	damage	repair	(and	hence	the	maintenance	
of	 genomic	 stability),	 regulation	 of	 apoptosis,	 cell	 proliferation,	 cell	 cycle	 arrest	 and	 cell	
migration	and	invasion[4,5].	In	this	context,	RPs	interact	with	non-ribosomal	components	of	
the	cell	and	trigger	a	special	cellular	program	that	could	eventually	result	 into	pathological	
consequences,	as	we	will	see	later.	
	
The	generation	of	new	ribosomes	is	extremely	demanding	in	terms	of	energy	expenditure	and	
cellular	 resources.	 It	 has	 been	 recently	 noted	 that	 ribosome	 biogenesis	 has	 a	 specific	
checkpoint	that	controls	the	proper	execution	of	the	whole	process.	Indeed,	the	perturbation	
at	many	steps	of	the	ribosomal	synthesis	determines	a	series	of	events	that	trigger	a	stress	
response	(also	known	as	Impaired	Ribosome	Biogenesis	Checkpoint	or	IRBC),	characterized	by	
a	loss	of	nucleolar	integrity	and	a	block	in	the	cell	proliferation[6,7].		
As	ribosome	activity	is	the	main	determinant	in	the	production	of	cellular	biomass,	it	is	not	
surprising	that	the	entire	process	is	often	hijacked	and	boosted	by	tumor	cells	to	more	rapidly	
provide	structural	and	catalytic	components	of	the	cell.	Both	impairment	and	hyperactivation	
of	ribosome	biogenesis	have	been	associated	with	deregulation	of	cell	cycle	and	proliferation,	
and	 surprisingly,	 the	 same	cellular	process	 in	 the	 two	different	 contexts	above	mentioned	
could	eventually	lead	either	to	an	oncogenic	or	a	tumor	suppressive	response,	respectively.	
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Steps	of	ribosome	biogenesis	
	
Ribosomes	are	classified	according	to	the	sedimentation	coefficient	expressed	in	Svedbergs	
(S).	Eukaryotic	ribosomes	are	larger	that	prokaryotic	ribosomes	and	this	is	also	reflected	by	
their	coefficient	of	sedimentation.	Mammalian	ribosomes	indeed	have	a	coefficient	of	80S,	
and	 a	 diameter	 of	 22nm.	 They	 are	 formed	 by	 two	 ribonucleoprotein	 subunits:	 the	 large	
subunit	 (60S)	 catalyzes	 the	 formation	 of	 peptide	 bonds,	 and	 the	 small	 subunit	 (40S)	 is	
accountable	for	decoding	mRNA	sequences	into	aminoacid	chains.	Four	rRNAs	(18S,	28S,	5.8S	
and	5S)	and	about	80	ribosomal	proteins	(RPs)	are	part	of	the	ribosome	structure.	
	
The	 rate	 of	 rRNA	 transcription	 is	 a	 limiting	 factor	 in	 the	 production	 of	 ribosomes[5].	 The	
process	starts	in	the	nucleolus,	with	the	transcription	of	the	polycistronic	precursor	45/47S	
pre-rRNA	by	the	RNA	polymerase	I[6].	The	45/47S	pre-rRNA	is	later	modified	and	processed	
by	small	nucleolar	RNAs	(snoRNAs)	and	other	protein	cofactors,	including	RPs,	giving	rise	to	
the	 three	 rRNAs:	 18S,	 28S	 and	5.8S.	Meanwhile,	 outside	 the	nucleolus	 but	 still	within	 the	
nucleoplasm,	a	second	rRNA	molecule,	the	5S,	is	transcribed	by	the	RNA	polymerase	III.	
	
These	steps	are	paralleled	by	the	transcription	of	RP	mRNAs	by	RNA	polymerase	II,	followed	
by	their	translation	in	the	cytoplasm.	At	this	stage,	the	different	RPs	are	imported	through	the	
nucleolar	pores	in	the	nucleus,	where	they	associate	with	the	45/47S	pre-rRNA	and	process	it	
into	the	two	subunits,	the	40S	and	the	60S.	Once	the	ribosomal	subunits	are	formed,	they	exit	
the	nucleus	through	the	nuclear	pores	and	enter	the	cytoplasm,	ready	to	start	executing	their	
function.	
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Figure	1:	Simplified	diagram	of	ribosome	biogenesis	process.	
	
The	 various	 rRNAs	 and	 ribosomal	 proteins	 are	 produced	 in	 equimolar	 amounts	 and	 their	
synthesis	is	tightly	regulated	by	a	variety	of	cellular	parameters.	
	
Translation	process	
	
Once	 the	 ribosomal	 subunits	 are	 released	 to	 the	 cytoplasm,	 they	are	 ready	 to	 initiate	 the	
translation	process.	Protein	biosynthesis	is	a	complex	process,	consisting	of	three	major	steps:	
initiation,	elongation	and	termination[7].	Eukaryotic	initiation	step	is	the	most	complex	phase	
of	the	translation	process,	and	can	occur	via	multiple	ways.	Cap-dependent	translation	is	the	
most	general	mechanism	of	translation	initiation[1].	Eukaryotic	initiation	factors	(eIFs)	are	a	
set	of	proteins	required	for	the	recruitment	of	the	40S	subunit	on	the	5’	end	of	the	mRNAs.	
The	 resulting	 43S	 complex	 scans	 the	 5’	 untranslated	 region	 (5’UTR)	 until	 finding	 the	 start	
codon	(AUG).	Once	the	AUG	codon	is	pinpointed	and	paired	with	the	anticodon	tRNA	at	the	
P-site,	the	60S	subunit	is	recruited	to	form	the	80S	ribosome	complex.	The	formation	of	this	
complex	allows	to	proceed	to	the	elongation	phase.	
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However,	 there	 is	 an	 alternative	mode	 of	 translation	 initiation,	 named	 Internal	 Ribosome	
Entry	 Site	 (IRES)-mediated	 translation[1],	which	 allows	 the	 translation	of	mRNAs	 in	 a	 cap-
independent	manner.	This	mechanism	spares	the	need	of	5’	end	recognition,	as	well	as	the	
mRNA	scanning	process,	by	directly	recruiting	the	40S	subunit	nearby	the	codon	where	the	
translation	must	be	initiated.	
	
In	 some	 physiological	 and	 pathophysiological	 conditions,	 IRES-dependent	 translation	 is	
stimulated,	supporting	a	robust	translation	of	mRNAs	when	the	cap-dependent	pathway	 is	
compromised	or	suppressed.	Diverse	studies	over	the	last	years	have	found	that	many	mRNAs	
containing	 IRES	 elements	 within	 their	 5’UTR	 actually	 encode	 proteins	 involved	 in	 stress	
protection	 and	 apoptosis[7],	 leading	 to	 the	 thought	 of	 IRES-dependent	 translation	 as	 an	
important	regulator	of	cell-fate	decisions	under	a	variety	of	conditions.		
	
P53	activation	and	the	Impaired	Ribosome	Biogenesis	Checkpoint	
	
The	role	of	p53	as	a	tumor	suppressor	in	humans	has	been	largely	studied	since	its	discovery;	
it	has	been	attributed	multiple	functions	such	as	DNA	repair	and	maintenance	of	the	genomic	
stability,	two	features	that	assigned	to	p53	the	role	of	“guardian	of	the	genome”.	As	a	result	
of	 its	 stabilization,	p53	can	operate	and	arrest	 the	cell	 cycle,	or	 induce	a	programmed	cell	
death	 (apoptosis).	 In	 addition	 to	 the	 above	 mentioned	 roles,	 upon	 a	 defined	 biological	
context,	p53	expression	 can	determine	 the	 induction	of	 senescence	or	a	 switch	 in	 cellular	
metabolism.	A	crucial	step	in	the	activation	of	p53	is	its	stabilization.	Under	normal	conditions,	
p53	 is	 efficiently	 ubiquitinated	 and	 degraded,	 resulting	 in	 its	 short	 half	 life.	 In	 contrast,	
following	 exposure	 of	 cells	 to	 stress,	 the	 levels	 of	 p53	 increase,	 predominantly	 due	 to	 its	
reduced	 degradation[8].	 Of	 the	 several	 ubiquitin	 ligases	 known	 to	 be	 involved	 in	 the	
degradation	of	p53,	a	central	role	is	played	by	Hdm2	(human	double	minute	2,	also	known	as	
Mdm2)[6,9,10,11].	In	unstressed	cells,	p53	levels	and	its	transcriptional	activity	are	negatively	
regulated	by	Hdm2[9].	At	the	same	time,	Hdm2	is	a	transcriptional	target	of	p53,	leading	to	
the	generation	of	a	negative	feedback	loop	that	keeps	p53	under	control[10].	
	
The	 first	 evidence	 for	 the	 existence	 of	 a	 cell	 cycle	 checkpoint	 in	 higher	 eukaryotes	 that	
responds	 to	 impaired	 ribosome	biogenesis	 came	 from	 studies	 in	out	 laboratory.	 The	 gene	
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encoding	 ribosomal	protein	RPS6	was	 conditionally	deleted	 in	 the	 liver	of	 adult	mice	and,	
following	partial	hepatectomy,	hepatocytes	failed	to	re-enter	the	cell	cycle	and	proliferate[4].	
Subsequent	studies	demonstrated	that	this	hindrance	in	proliferation	is	due	to	the	activation	
of	 a	 p53-dependent	 checkpoint	 that	 is	 triggered	 by	 a	 specific	 pre-ribosomal	 complex	
constituted	 by	 the	 ribosomal	 proteins	 RPL11,	 RPL5	 and	 the	 5S	 rRNA.	 In	 normal	 growing	
conditions,	this	complex	is	 incorporated	into	the	pre-60S	subunit,	giving	rise	to	a	complete	
60S	subunit,	whereas	upon	a	ribosome	biogenesis	insult,	it	is	redirected	to	bind	and	inhibit	
Hdm2,	resulting	into	the	stabilization	of	p53	levels	and	its	transcriptional	activity[14,15,16].	
This	checkpoint	was	recently	termed	Impaired	Ribosome	Biogenesis	Checkpoint	(IRBC)[12].		
	
5S	 rRNA	 is	also	 involved	 in	 the	 regulation	of	another	 component	of	 the	p53	pathway;	 the	
transcriptional	 regulator	 HdmX.	 In	 normal	 conditions,	 the	 formation	 of	 the	 Hdm2-HdmX	
heterodimer	 represses	 the	 transcriptional	 activity	 of	 p53	 and	 promotes	 its	
polyubiquitinization	and	degradation.	The	binding	of	RPL11	to	Hdm2,	besides	blocking	its	E3-
ligase	 activity,	 also	 facilitates	 HdmX	 degradation,	 strengthening	 p53’s	 hyperactivation.	
However,	 when	 HdmX	 is	 bound	 to	 5S	 rRNA,	 it	 becomes	 unaffected	 by	 RPL11-Hdm2	
degradation[9].	
	
Ribosome	biogenesis	in	cancer	
	
The	fact	that	mRNA	expression	patterns	change	when	the	translational	machinery	becomes	
quantitatively	and/or	qualitatively	altered	provides	us	an	opening	to	address	how	defects	in	
ribosome	biogenesis	could	be	directly	 implicated	 in	cancer.	Transformation	of	normal	cells	
into	cancer	cells	is	a	pretty	complex	process.	It	requires	the	dysregulation	of	oncogenes	and/or	
tumor	suppressors’	activity,	through	multiple	mechanisms,	resulting	in	the	impairment	of	the	
cellular	proliferation	and	survival	response,	an	alteration	in	metabolism	and	a	promotion	of	
invasion	into	contiguous	tissue.	
	
Among	 all	 the	 possible	mechanisms	 by	which	 a	 normal	 cell	 transforms	 into	 a	 cancer	 cell,	
ribosome	biogenesis	plays	an	important	role.	This	is	not	surprising,	considering	that	ribosome	
synthesis	constitutes	the	anabolic	engine	for	the	biomass	production	and	hence	for	the	cell	
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growth	and	proliferation.	Many	key	proto-oncogenes	(such	as	c-Myc)	and	tumor	suppressors	
(such	as	p53)	have	been	found	to	regulate	this	process,	as	we	previously	introduced.	
	
c-Myc	and	the	components	of	the	PI3K-mTORC1	signaling	pathway	stand	out	among	these	key	
factors,	 as	 mentioned	 above.	 Deregulation	 of	 Myc	 activity	 is	 one	 of	 the	 most	 frequent	
oncogenic	 lesions	 underlying	 human	 cancers[13].	 With	 respect	 to	 Myc,	 it	 controls	 the	
expression	of	several	components	of	the	protein	synthetic	machinery	(including	RPs,	initiation	
factors	of	translation,	RNA	polymerase	I	and	ribosomal	DNA	transcription,	RNA	polymerase	II	
and	III).	All	these	events	point	at	a	pathological	role	for	Myc	in	tumorigenesis,	through	the	
stimulation	 of	 ribosome	 biogenesis.	 Indeed,	 uncontrolled	 proliferation,	 a	 hallmark	 of	 all	
cancers,	 requires	 a	 continuous	 supply	 of	 structural	 and	 catalytic	 cellular	 components	 to	
generate	the	cell	mass	required	for	replication.	As	ribosomes	are	the	centers	for	production	
of	cellular	biomass,	it	is	not	surprising	that	many	cancer	promote	ribosome	biogenesis	during	
the	process	of	tumorigenesis.	
	
Recent	evidence	 suggests	 that	 the	RPL5-RPL11-Hdm2-p53	pathway	may	monitor	excessive	
ribosome	biogenesis	to	prevent	tumorigenesis[9].	c-Myc,	as	the	regulator	of	the	45/47S	pre-
rRNA,	 5S	 rRNA	 and	 all	 RP	 mRNA	 transcription,	 becomes	 directly	 associated	 to	 ribosome	
biogenesis.	 Several	 experiments	 carried	 out	 using	 mouse	 models	 of	 B-cell	 lymphoma	
predisposition	overexpressing	c-Myc[13]	demonstrated	how	c-Myc	is	capable	of	upregulating	
ribosome	 biogenesis	 in	 this	 tumor	 context.	 An	 RPL24-haploinsufficiency	 background,	 that	
reduces	 the	 ribosome	 production	 and	 the	 protein	 synthetic	 capacity	 of	 B-cell	 to	 a	
premalignant	 state,	 dramatically	 reduces	 the	 tumorigenic	 burden	 determined	 by	 c-Myc	
upregulation.	 Importantly,	 Macias	 et	 al.	 demonstrated	 that	 c-Myc	 driven	 B-cell	
lymphomagenesis	was	further	boosted	in	a	genetic	context	impaired	for	the	IRBC	response.	
The	most	plausible	hypothesis	is	that	RPL5-RPL11-Hdm2-p53	pathway	monitors	the	excessive	
ribosome	biogenesis	in	order	to	counteract	tumorigenesis[14].	All	these	studies	prompted	the	
field	to	consider	the	upregulation	of	ribosome	biogenesis	as	an	oncogenic	event.	
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Ribosomopathies	
	
A	 category	of	 anemic	 syndromes	 like	Diamond	Blackfan	Anemia	 (DBA),	 5q–	 syndrome	and	
Schwachman	 Diamond	 Syndrome	 (SDS),	 characterized	 by	 bone	 marrow	 failure,	 growth	
retardation	 and	 cancer	 later	 in	 life,	 are	 associated	with	 haploinsufficient	mutation	 in	 RPs	
haploinsufficiency.	 For	 this	 last	 reason,	 they	 are	 also	 categorized	 as	 Ribosomopathies.	
Surprisingly,	despite	the	congenital	mutation	is	common	to	all	tissues,	only	highly	proliferating	
tissues	are	impaired	by	altered	ribosome	biogenesis	determined	by	the	RP	mutation.	
Studies	on	animal	models	of	defective	ribosome	biogenesis	raised	evidences	suggesting	that	
activation	 of	 p53	 IRBC-dependent	 underlies	 the	 pathogenesis	 of	 the	 human	 DBA,	 5q–	
syndrome	and	SDS[15].	Conditional	deletion	of	RPS6	in	mouse	bone	marrow	can	recapitulate	
the	 features	 of	 DBA.	 Intriguingly,	 p53-/-	 background	 can	 rescue	 most	 of	 the	 phenotypes	
associated	with	DBA,	underscoring	the	role	of	p53	checkpoint[16].	
Importantly,	accumulation	of	nuclear	p53	has	been	 found	 in	marrow	biopsy	 samples	 from	
these	patients,	suggesting	the	basis	for	the	failure	of	erythropoiesis	in	these	diseases.	
	
Any	mutation	affecting	components	involved	in	ribosome	biogenesis	will	potentially	lead	to	
either	a	reduction	of	the	ribosome	number,	or	to	aberrant	ribosomes,	directly	affecting	the	
protein	 translation	process[15].	 In	case	of	having	a	 reduction	 in	 the	number	of	 ribosomes,	
there’s	a	competition	between	different	kinds	of	mRNAs.	In	this	situation,	TOP	mRNAs	come	
into	play.	mRNAs	containing	a	5’TOP	sequence	at	the	5’UTR	region	have	a	higher	affinity	for	
specific	 translational	 machinery	 than	 the	 ones	 lacking	 it.	 We	 must	 remember	 that	 these	
mRNAs	 usually	 codify	 for	 almost	 all	 RPs	 and	many	 translational	 factors,	 as	 stated	 before.	
Qualitative	defects	 in	 ribosomes	might	affect	 the	 translation	of	 specific	 target	mRNAs[15].	
Thus,	 it	 is	 reasonable	 to	assume	that	 specific	mutations	 that	 lead	 to	a	 reduced	number	of	
functional	ribosomes	in	the	cell	would	alter	not	only	the	rate	of	total	protein	synthesis,	but	
also	the	patterns	of	translated	mRNAs.	
	
In	ribosomopathies,	the	most	affected	tissues	will	be	the	ones	with	a	high	cell	division	rate	
(associated	 with	 a	 high	 ribosome	 production	 rate),	 such	 as	 bone	marrow.	 Of	 course,	 the	
degree	 of	 damage	 in	 ribosome	 synthesis	 caused	 by	 any	mutation	 affecting	 a	 component	
involved	 in	 ribosome	 biogenesis	 will	 depend	 on	 the	 relative	 expression	 levels	 of	 that	
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component,	its	requirement	in	the	ribosome	biogenesis	process	or	the	severity	of	the	mutant	
allele.	Studies	on	human	erythroid	progenitor	cells	from	DBA,	5q–	syndrome	and	SDS	patients	
evinced	a	p53	activation	after	the	depletion	of	RPs[1,15].	
	
As	 it	was	mentioned	before,	DBA	 is	 a	 congenital	disease	 that	 leads	 to	macrocytic	anemia,	
caused	by	the	reduction	of	erythroid	precursors	in	bone	marrow[15,17].	About	half	of	these	
patients	 suffer	 from	malformations	 in	 other	 organs.	 The	 same	mechanism	underlying	 this	
pathology	also	predisposes	not	only	 these	patients,	but	5q–	syndrome	and	SDS	patients	as	
well,	to	develop	acute	myeloid	leukemia	(AML)	and	solid	malignancies[18].	
	
Ribosomal	Proteins	and	5’TOP	translation	
	
Given	the	central	importance	of	maintaining	a	functional	and	robust	translation	machinery,	it	
is	reasonable	to	believe	that	the	translation	of	RP	mRNAs	must	be	carried	out	in	an	organized	
and	hierarchical	manner[19].	The	finding	of	5’TOP	nucleotide	consensus	at	the	transcriptional	
start	sites	of	RP	mRNAs	supported	this	hypothesis.	The	broad	category	of	5’TOP	mRNAs	are	
characterized	by	containing	a	5’	 terminal	oligopyridimidine	 (5’TOP)	 sequence	at	 the	5’UTR	
region.	Several	studies	in	vertebrates	found	that	many	RPs,	as	well	as	many	genes	involved	in	
translation,	actually	are	encoded	by	5’TOP	mRNAs.	
	
Several	 studies	have	addressed	 the	 link	between	 the	 translation	of	 5’TOP	mRNAs	and	 the	
mTOR	 pathway,	 such	 as	 upon	 mTOR	 inhibition[20],	 or	 under	 aminoacid	 deprivation[21].	
Recently,	 the	 RNA	 binding	 protein	 LARP1,	 a	 protein	 belonging	 to	 the	 La-related	 family	 of	
proteins[19],	 was	 successfully	 co-immunoprecipitated	 with	 eIF4F	 complex,	 which	 was	
previously	believed	to	be	involved	in	the	5’TOP	mRNA	regulation	and	mTOR	network.	Other	
studies	in	HEK293,	where	LARP1	was	depleted,	corroborated	that	the	levels	and	translation	of	
5’TOP	mRNAs	are	subject	to	the	expression	of	LARP1[22,23].	The	same	study	also	showed	how	
levels	of	5’TOP	mRNAs	dropped	 in	 the	absence	of	LARP1,	as	well	as	 their	association	with	
polysomes.	At	the	same	time,	other	studies	have	demonstrated	how	the	mammalian	target	
of	rapamycin	complex	1	(mTORC1)	is	also	able	to	drive	the	translation	of	RP	mRNAs,	among	
its	countless	other	 functions[24,25].	Recent	genome-wide	studies	show	that	5’TOP	mRNAs	
constitute	a	considerable	share	of	the	mTORC1	translatome.	In	light	of	these	results,	it	was	
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hypothesized	that	emergent	5’TOP	mRNA	translation	could	play	a	critical	role	in	the	cell	cycle	
checkpoint	controlling	ribosome	biogenesis.	
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OBJECTIVES	
	
A	key	step	of	Ribosome	Biogenesis	is	the	synthesis	of	ribosomal	proteins	(RPs).	The	availability	
of	RPs	in	the	cell	determines	the	rate	at	which	new	ribosomes	are	produced.	Moreover,	by	
means	of	an	increase	in	ribosome	biogenesis,	many	external	stimuli	that	prompt	the	cell	to	
proliferate,	 can	 rapidly	 control	 the	production	of	 biomass	 required	 for	 cell	 duplication,	 by	
stimulating	 the	 translation	of	RP	mRNAs	and	hence	 the	production	of	more	 ribosomes.	 In	
order	 to	 understand	 how	 RP	 mRNAs	 translation	 is	 regulated	 upon	 different	 anabolic	
conditions,	the	following	objectives	have	been	outlined:	
	
1	–	Overview	of	the	approaches	utilized	to	study	mRNA	translation:	polysome	profiling	and	
ribosome	profiling	analyses.	
	
2	–	Analysis	of	ribosomal	protein	mRNA	translation	in	cancer	cells	and	analysis	of	ribosome	
biogenesis.	
	 	
	 15	
MATHERIALS	AND	METHODS	
	
The	present	work	 is	mainly	based	on	 the	 collection	of	bibliographic	 information	extracted	
from	 PubMed	 and	 Scopus	 databases.	 The	 initial	 search	 terms	 in	 the	 first	 screening	 were	
ribosome	biogenesis	and	cancer.	This	initial	selection	provided	a	set	of	scientific	articles	that	
leaded	to	other	articles,	by	 looking	at	the	citations	within	their	bibliography.	This	step	was	
repeated	 as	 much	 as	 necessary,	 and	 the	 obtained	 information	 was	 occasionally	
complemented	with	new	searches	over	specific	topics.	This	easy	and	rapid	method	not	only	
provided	a	wide	source	of	information	to	learn	about	the	topic,	but	also	allowed	to	come	up	
with	studies	specifically	addressing	our	subject	matter.	
	
This	section	also	introduces	a	classical	technique	that	I	was	able	to	attend	at	the	Laboratory	
of	Cancer	Metabolism	(IDIBELL):	the	polysome	profiling.	In	this	regard,	I	have	assisted	many	
steps	of	the	work	performed	by	thesis	director	with	respect	to	polysome	profile	analysis	of	
ribosomal	protein	mRNAs.	This	technique	is	used	to	study	the	differential	translational	output	
of	the	mRNAs	of	interest	in	two	or	more	conditions,	and	it	has	been	part	of	many	experiments	
performed	 in	 the	 scientific	 articles	 discussed	 in	 this	work.	 The	 protocol	 of	 this	 technique,	
disclosed	in	the	upcoming	section,	has	been	acquired	from	Faye	and	coworkers’	review[26]	
and	adapted	to	the	gradient	fractionation	system	of	the	lab.		
	
Polysome	profiling	protocol	
	
Polysome	 profiling	 is	 a	 technique	 used	 to	 investigate	 translational	 changes	 of	 the	
transcriptome	under	different	conditions.	Basically,	this	technique	consists	in	the	preparation	
of	cell	lysates	in	a	way	that	preserves	the	association	of	ribosomes	with	the	mRNAs	that	are	
in	the	process	of	translation	at	the	time	of	lysis.	By	means	of	ultracentrifugation	on	a	sucrose	
gradient,	 that	enables	 the	 separation	of	 ribosomes	associated	 to	mRNAs	 (polysomes)	 as	 a	
function	of	their	number,	a	260nm	OD	profile	of	the	ribosomal	separation	is	obtained,	and	a	
collection	of	the	non-polysomal	vs	polysomal	fractions	is	then	operated.	Fractions	are	then	
processed	for	RNA	analysis.	The	principle	assumed	by	this	technique	is	as	follows:	the	more	
ribosomes	are	associated	 to	a	 transcript,	 the	more	 the	mRNA	 is	 translated.	Cycloheximide	
(CHX),	which	blocks	the	steps	of	translational	initiation	and	elongation,	is	used	just	before	lysis	
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to	“freeze”	the	positioning	of	the	ribosomes	on	the	mRNAs.	In	addition,	standard	precautions	
are	needed	in	the	execution	of	the	protocol	to	protect	RNA	against	degradation	by	RNases.		
	
1.	 Preparation	 of	 solutions.	 In	 this	 step,	 basic	 solution	 and	 two	 sucrose	 solutions	 with	
different	 concentrations	 (10%	 and	 50%)	 are	 prepared.	 The	 day	 of	 the	 experiment,	 fresh	
polysomal	lysis	buffer	is	prepared.		
	
2.	Preparation	of	sucrose	gradient.	In	this	step,	an	automated	gradient	machine	is	used.	The	
tubes	are	placed	 in	a	 fitting	 rack	on	a	 steady	 surface,	allowing	 the	 layering	of	 the	 sucrose	
solutions.	 Two	 syringes	 are	 filled	 with	 the	 two	 different	 sucrose	 solutions,	 respectively.	
Afterwards,	a	specific	volume	of	the	sucrose	solutions	(starting	with	the	10%	solutions	and	
following	with	the	50%	solution)	are	added	to	the	bottom	of	the	tubes.	It	is	important	to	avoid	
bubbles.	 The	 10%	 sucrose	 solution	 stays	 at	 the	 top	 of	 the	 tube,	 due	 to	 its	 lower	 density,	
whereas	the	50%	sucrose	solution	stays	at	the	bottom.	Gradients	are	formed	by	the	gradient	
master	machine.	The	tubes	are	kept	at	4ºC	for	30	minutes.		
	
3.	Cell	lysis.	The	day	before	the	experiment,	cells	are	plated	in	order	to	achieve	an	optimal	cell	
density	the	following	day.	The	day	of	the	experiment,	cells	are	incubated	in	CHX	+	media	for	
5	minutes	 at	 37ºC	 and	 5%	 CO2	 to	 arrest	 and	 stabilize	 polysomes.	 Quickly	 after,	 media	 is	
removed	and	the	cell	plates	are	placed	on	ice	and	washed	with	ice	cold	phosphate	buffered	
saline	(PBS)	supplemented	with	CHX.	Additional	10	ml	of	PBS	mixed	with	CHX	is	added	to	the	
plates	before	proceeding	to	cell	scraping.	The	total	volume	of	the	plates	is	transferred	to	a	
single	centrifuge	tube,	previously	placed	on	ice.	
	
4.	Ultracentrifugation.	Samples	are	subjected	to	centrifugation	at	4ºC	at	high	speeds	in	order	
to	obtain	supernatants	containing	the	cytoplasmic	extracts	enriched	of	polysomes.	A	protein	
determination	is	performed	and	equal	amounts	of	protein	extracts	are	loaded	onto	sucrose	
gradients.	The	gradients	are	then	ultracentrifuged	at	35,000	rpm	for	3	hours	at	4ºC.	
	
5.	Gradient	fractionation.	This	step	requires	the	set-up	of	the	fractionation	instrument	and	
the	“blanking”	of	the	spectrophotometer	set	at	260	nm	with	water.	Once	the	parameters	are	
set,	the	instrument	collects	the	ultracentrifuged	samples	starting	from	the	upper	part	of	the	
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gradient	 (10%	 sucrose)	 and	 proceeding	 till	 the	 bottom	 of	 the	 tube	 (50%	 sucrose).	 	While	
fractionating	 the	 gradient	 into	 1ml	 aliquots,	 the	 sucrose	 solution	 is	 read	 by	 the	
spectrophotometer	 which	 generate	 a	 profile	 of	 rRNA	 absorbance	 across	 the	 gradient.	 	 A	
sample	from	each	fraction	is	stored	for	following	RNA	analysis.		
	
6.	 Isolation	 of	 RNA	 from	 sucrose	 fractions.	 Equal	 amounts	 of	 phenol:chloroform:isoamyl	
alcohol	are	added	to	each	sucrose	fraction	to	remove	proteins.	After	several	centrifugations	
and	removal	of	the	phenolic	phase,	the	fractions	are	added	with	one	volume	of	Isopropanol	
and	 left	 overnight	 at	 -20ºC	 for	 precipitation.	 The	 following	day,	 RNA	pellet	 is	 obtained	by	
centrifugation,	washed,	air	dried,	and	finally	resuspended	with	RNase-free	water.		
The	RNA	derived	from	each	fraction	is	then	analyzed	by	Northern	Blot	or	RT-qPCR	analyses	
according	 to	 specific	 protocols,	 and	 relative	 amounts	 of	 the	 mRNAs	 of	 interest	 can	 be	
determined.	
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RESULTS	AND	DISCUSSION	
	
How	to	measure	the	translational	rate	of	an	mRNA?	
	
Over	the	last	fifteen	years,	global	gene	expression	analysis,	by	means	of	microarray	and	RNA-
seq	 approaches,	 has	 allowed	 to	 characterize	 unbiasedly	 the	 expression	 profile	 in	 a	 huge	
number	of	biological	contexts,	either	physiological	and	pathological.	This	approach	has	been	
of	 fundamental	 importance	 to	 broaden	 the	 point	 of	 view	 of	 researchers	 from	 the	 single	
protein	 to	 the	 network	 of	 proteins.	 However,	 the	 assumption	 done	 in	 global	 RNA-based	
measurement	is	that	the	mRNA	levels	parallel	the	amounts	of	cognate	protein	synthesized	in	
the	cell.	So	do	the	changes	observed	in	the	transcriptome	composition	when	comparing	two	
different	conditions.	Although	this	principle	holds	true	for	the	major	part	of	the	transcriptome,	
several	subsets	of	mRNAs	do	not	always	correlate	with	the	protein	levels,	due	to	regulatory	
mechanisms	 that	 control	 their	 translation.	 Many	 recent	 studies	 have	 demonstrated	 in	
different	 systems	 the	 importance	 of	 translational	 regulation	 as	 a	 layer	 of	 control	 of	 gene	
expression	that	can	quickly	convert	genetic	information	into	proteins.	In	this	regards	the	need	
of	determining	the	translation	profile	of	a	transcriptome	has	prompted	the	field	to	develop	
techniques	that	could	address	this	biological	problem.	Here,	 two	gold	standard	techniques	
that	allow	to	determine	the	level	of	translation	of	mRNAs	will	be	described.	After	a	brief	insight	
into	the	polysome	profiling	protocol,	this	technique,	together	with	the	ribosome	profiling,	will	
be	discussed	in	the	following	sections,	supported	by	two	illustrative	studies	that	will	help	to	
fully	understand	these	experimental	approaches	for	the	translatome	study.		
	
Polysome	Profiling	
	
Polysome	profiling	is	a	standard	technique	used	to	separate	cellular	transcripts	as	a	function	
of	 the	 number	 of	 ribosomes	 attached	 to	 them,	 by	means	 of	 a	 sucrose	 gradient[27].	 The	
initiation	process	is	a	limiting	step	in	mRNA	translation,	therefore,	the	degree	of	associated	
ribosomes	for	a	specific	mRNA	will	give	us	an	 idea	of	the	translation	rate	of	the	mRNAs	of	
interest.	By	preserving	the	associations	of	actively	translating	ribosomes,	the	technique	allows	
to	 capture	 mRNA	 translation	 and	 to	 distinguish	 between	 highly	 translated	 and	 poorly	
translated	transcripts[26].	The	sucrose	gradient	centrifugation	enables	separating	polysomes	
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from	non-polysomal	fraction.	The	latter	is	resolved	into	free	mRNA	and	RNPs	fraction	and	the	
free	 40S,	 free	 60S	 subunits,	 and	 80S	 monosomes	 (Figure	 2).	 Downstream	 of	 polysomal	
fractionation,	 RTq-PCR	 and	 Northern	 Blot	 are	 two	 standard	 techniques	 that	 are	 usually	
implemented	to	monitor	and	quantify	the	distribution	of	different	mRNAs	within	the	gradient.	
When	 coupled	with	 immunoblot	 analysis,	 polysome	profiling	will	 also	 enable	 the	 study	of	
proteins	and	complexes	associated	with	the	process	of	translation.		
	
Figure	2:	General	overview	of	ultracentrifuged	sample	through	a	linear	10-50%	sucrose	density	
gradient	(A)	and	gradient	fractionation	at	254nm	absorbance	(B).	
	
This	technique	is	widely	used	for	initial	screenings	of	translational	changes	in	cultured	cells	
and	tissues,	as	well	as	tracking	the	translational	status	of	specific	mRNAs	whose	 identity	 is	
known[27].	 For	 instance,	 Damgaard	 and	 coworkers[28]	 used	 polysome	 profiling	 to	
demonstrate	that	the	RNA	binding	proteins	TIA-1	and	TIAR	can	associate	to	5’TOP	mRNAs	by	
binding	to	their	5’	element	when	cells	are	cultured	in	absence	of	amino	acids.	The	authors	
show	 that	 this	 association	 determines	 a	 release	 of	 these	 transcripts	 from	 polysomes	 and	
hence,	a	reduction	in	the	synthesis	of	the	cognate	proteins.	The	team	quantified	the	levels	of	
three	specific	mRNAs	containing	the	5’TOP	sequence	(RPL23a,	RPL12/36	and	PABPC1)	in	the	
polysomal	 fractions	 upon	 aminoacid	 starvation.	 β-actin	 and	 calmodulin	 2	 mRNAs	 (lacking	
5’TOP	sequence	but	containing	a	binding	site	for	TIA-1	and	TIAR	at	their	3’	end)	were	used	as	
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controls.	 Figure	 3	 shows	 the	 results	 from	 northern	 blots	 of	 sucrose	 gradient	 polysomal	
fractionations.		
	
Figure	3:	Northern	blots	from	sucrose	gradient	polysomal	fractions	of	RPL23a,	RPL12/36	and	PABPC1	
mRNAs	upon	exposure	to	full	medium	(Full)	and	amino	acid	starvation	(–AA)	medium,	in	the	presence	
of	siNT	(control)	and	siTIA-1/R	knockdowns	(A);	equivalent	northern	blots	from	β-actin	and	calmodulin-
2	mRNAs	(B).	Figure	from	Daamgard	et	al.[28].	
	
However,	just	like	other	techniques,	polysome	profiling	also	has	its	limitations.	This	complex	
and	 arduous	method	 requires	 specialized	 equipment	 that	may	 not	 be	 accessible	 to	 every	
laboratory.	 Moreover,	 it	 demands	 a	 large	 sample	 size,	 adding	 an	 extra	 difficulty	 to	 the	
experiments	based	on	low	abundance	of	tissue	samples,	such	as	cancer	tissue	biopsies[27].		
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Ribosome	Profiling	
	
Ribosome	Profiling	(also	called	Ribosome	Footprinting)	was	recently	developed	by	Nicholas	
Ingolia	 and	 Jonathan	Weissman	 at	 UCSF[29]	 and	 enables	 determining	 the	 engagement	 in	
translation	at	a	global	level	of	the	whole	transcriptome	of	a	cell	and	the	position	of	ribosomes	
at	 near	 nucleotide	 resolution	 on	 each	 transcript[27].	 Similarly	 to	 polysome	 profiling,	 this	
genome	wide	technique	allows	monitoring	cellular	translation	process	and	predicting	protein	
abundance.		
The	protocol	of	ribosome	profiling	requires	the	preparation	of	a	library	of	the	RNA	fragments	
occupied	by	ribosomes.	An	enzyme	with	RNAse	activity	is	added	to	the	cell	extracts,	previously	
prepared	as	for	polysome	profiling.	Upon	controlled	reaction	condition,	every	RNA	sequence	
that	 is	 not	 protected	 by	 ribosome	 occupancy,	 is	 exposed	 to	 RNAse	 activity	 and	 is	 then	
degraded.	 Under	 this	 setting,	 the	 ribosome	 protection	 generates	 footprints	 in	 the	 whole	
transcriptome	 representing	 site	 of	 translation	 or	 stallment.	 Once	 the	 RNA	 footprints	 are	
purified,	these	are	converted	into	a	cDNA	library	that	is	then	subjected	to	deep	sequencing,	
thus	enabling	the	determination	of	the	amount	of	each	protected	fragment	and	their	exact	
position	along	the	mRNA	sequence.	(Figure	4).	
	
	
Figure	4:	General	overview	of	ribosome	profiling	process.	Samples	are	treated	with	RNase	to	digest	
unprotected	 mRNA.	 Ribosome	 protected	 fragments	 (RPFs)	 are	 isolated	 and	 size-fractionated	 and	
eventually	sequenced	by	RNA-seq.	Figure	taken	from	[29].	
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This	 powerful	 approach	 has	 led	 to	 the	 discovery	 of	 novel	 coding	 transcripts,	 new	 protein	
isoforms	and	the	accurate	determination	of	elongation	and	decoding	speeds,	among	many	
other	 features	 and	 functions.	 Furthermore,	 the	 possibility	 of	 discerning	 the	 initiation	 and	
elongation	events	allowed	the	discovery	of	countless	new	uORFs	and	alternative	start	codons	
involved	with	ribosomes[30].	This	is	the	case	of	a	study	by	Hsieh	and	coworkers[31]	in	PC3	
cells,	 where	 ribosome	 profiling	 was	 used	 to	 compare	 the	 effect	 of	 two	 mTOR	 inhibitors	
(rapamycin	and	PP242)	over	a	3h	treatment	period	through	the	sequencing	of	RPFs	(ribosome	
protected	fragments).	The	method	enabled	the	determination	of	mRNA	abundance	(RNA-seq	
reads),	 ribosome	 occupancy	 (RPF	 reads)	 and	 translational	 efficiency	 (RPF	 reads/RNA-seq	
reads).	 Data	 treatment	 revealed	 a	 significant	 higher	 number	 of	 target	 mRNAs	 selectively	
decreased	at	the	translational	level	upon	PP242	treatment	compared	to	rapamycin	treatment,	
as	shown	in	figure	5,	meaning	a	higher	effectiveness	for	mTOR	inhibition.	Moreover,	ribosome	
profiling	 revealed	 the	 presence	 of	 two	 regulatory	 motives	 within	 the	 5’UTR	 sequence	 of	
mTOR-sensitive	mRNAs:	68%	of	them	contained	a	5’TOP	sequence,	against	63%	containing	
PRTE	 (pyrimidine-rich	 translational	 element).	 When	 looking	 for	 5’TOP	 and	 PRTE	 together	
within	the	same	5’UTR,	it	was	found	that	89%	of	the	target	mRNAs	contained	both	sequences,	
making	 the	 presence	 of	 one	 or	 preferably	 both	 sequences	 a	 strong	 predictor	 for	 mTOR	
responsiveness.	
	
	
Figure	5:	Comparison	between	RNA	levels	(left)	and	translational	efficiency	(right)	upon	treatment	with	
PP242	(ATP	site	mTOR	inhibitor)	against	rapamycin	(allosteric	mTOR	inhibitor)	in	PC3	cells.	Figure	taken	
from	[31].	
	
	 23	
Finally,	 translationally	 regulated	mTOR-sensitive	mRNAs	were	 classified	 according	 to	 their	
function.	 Among	 all	 the	 different	 functions,	 protein	 synthesis	 and	 cell	 invasion/metastasis	
were	 the	 predominant	 classes	 of	 translationally	 regulated	mRNAs,	 elucidating	 the	 cellular	
invasive	features	of	human	prostate	cancer	cells	that	hyperactivated	mTOR	controls	at	the	
translational	level.	
	
Even	 though	 ribosome	profiling	 is	 presented	 as	 a	 powerful	 technique,	 it	 is	 not	 exempt	 of	
limitations.	As	with	polysome	profiling,	specialized	equipment	is	required,	and	the	complex	
methodology	 demands	 a	 laborious	 and	 intensive	 work	 as	 much	 as	 solid	 extensive	
bioinformatics.	
	
Polysome	Profiling	of	Ribosomal	Protein	mRNAs	upon	mTOR	inhibition	
	
In	many	tumor	types	the	mTOR	pathway	is	hyperactivated.	The	number	of	anabolic	processes	
that	mTOR	controls	have	made	it	an	attractive	therapeutic	target	that	is	now	exploited	in	the	
clinic[32].	In	this	regard,	the	effects	of	mTOR	inhibitors	on	cell	proliferation	are	mediated	by	
blocking	 many	 steps	 of	 ribosome	 biogenesis	 capacity	 of	 the	 cell.	 RPs	 synthesis	 is	 mainly	
controlled	at	the	translational	level,	and	mTOR	signaling	is	in	charge	of	sustaining	RP	mRNA	
translation	 by	 virtue	 of	 the	 5’TOP	 sequence	 element	 that	 almost	 all	 RPs	 possess	 at	 the	
transcriptional	 start	 site	 (TSS).	 One	 of	 the	 research	 interests	 of	 the	 Laboratory	 of	 Cancer	
Metabolism	(LMC)	 is	unraveling	the	mechanism	by	which	mTOR	controls	the	translation	of	
5’TOP	mRNAs	and	how	the	 inhibition	of	this	pathway	can	be	efficiently	exploited	to	attack	
tumor	spreading	and	relapse.	During	my	stay	at	the	LMC	I	have	been	following	the	work	of	my	
thesis	director,	who	showed	me	how	the	engagement	in	translation	of	an	RP	mRNA	in	a	cancer	
cell	line	upon	TOR	inhibition	is	measured.	
	
Cells	from	HCT116	human	colon	adenocarcinoma	cell	line	were	cultured	in	full	medium	and	in	
full	 medium	 supplemented	 with	 the	 mTORC1	 allosteric	 inhibitor	 rapamycin,	 at	 the	
concentration	 of	 40nM	 for	 16h.	 Cells	 were	 harvested	 and	 polysomal	 lysates	 prepared	
according	to	the	protocol	described	above.	Equal	amounts	of	polysomal	lysates	were	applied	
to	 sucrose	 linear	 gradients	 and	 ultracentrifuged,	 then	 fractionated	 with	 a	 Gradient	
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Fractionation	Unit	and	the	abundance	of	rRNA	was	determined	by	measuring	the	absorbance	
at	260nm	with	a	spectrophotometer	(Figure	6).	
	
	
Figure	6:	Polysome	profiles	of	HCT116	cell	lysate	(black)	and	HCT116	rapamycin-treated	cells	(red).	
	
Every	sucrose	gradient	was	fractionated	in	12	samples	and	each	fraction	was	added	with	an	
exogenous	Luciferase	RNA	that	served	as	normalization	control.	RNA	was	extracted	from	all	
fractions	and	subjected	to	retro-transcription.	Distribution	of	a	5’TOP	mRNA	(RPL11)	and	a	
non-5’TOP	mRNA	(GAPDH)	was	determined	by	qPCR	and	the	amounts	of	RPL11	or	GAPDH	
cDNAs	 normalized	 to	 luciferase	 cDNA	 spike	were	 calculated	 in	 each	 fraction.	 As	 shown	 in	
Figure	7,	RPL11,	which	is	distributed	in	a	proportion	of	40%/60%	non-polysomes/polysomes	
respectively	in	control	cells,	is	redistributed	in	favor	of	the	non-polysomal	part	of	the	gradient	
upon	rapamycin	treatment,	evidencing	the	predicted	translational	inhibition	of	5’TOP	mRNA	
when	mTORC1	 signaling	 is	 pharmacologically	 blocked.	A	non-5’TOP	mRNA	 such	as	GAPDH	
didn’t	show	such	redistribution	upon	TOR	inhibition,	but	only	a	sharp	drop	in	large	polysomes,	
presumably	due	to	general	effect	of	rapamycin	on	global	protein	synthesis	rate.	
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Figure	7:	RT-qPCR	analysis	from	gradients	shown	in	Figure	6.	RPL11,	GAPDH	and	luciferase	cDNAs	were	
determined	 in	each	 fraction	and	 the	 ratio	RPL11/Luciferase	 (left	panel)	or	GAPDH/Luciferase	 (right	
panel)	were	calculated.	
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CONCLUSIONS	
	
1	–	Polysome	profiling	and	ribosome	profiling	are	two	techniques	that	allow	the	study	and	
analysis	of	the	translatome	in	a	different	degree.	While	polysome	profiling	is	used	for	initial	
screenings	of	translational	changes	and	for	tracking	the	translational	status	of	already	known	
mRNAs,	ribosome	profiling	offers	the	possibility	of	constructing	RNA	libraries	from	ribosome	
protected	 fragments,	 providing	 plenty	 of	 information	 about	 the	 translation	 process	 and	
leading	to	the	discovery	of	new	elements	and	sequences.	
	
2	–	Inhibition	of	mTOR	signaling	pathway	using	rapamycin	reduces	the	translation	of	5’TOP	
mRNAs	 in	 HTC116	 cancer	 cells.	 As	 almost	 all	 RPs	 (including	 RPL11)	 contain	 this	 5’TOP	
sequence,	 this	 effect	 negatively	 impacts	 the	 synthesis	 RPs	 and	 hence	 of	 ribosomes,	 and	
consequently	slow	down	the	proliferation	rate	of	cancer	cells.	This	effect	can	be	measured	by	
using	the	polysome	profiling	technique.	
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